Berezin Alexander, Zulli Anthony, Kerrigan Steve, Petrovic Daniel, Kruzliak Peter
Internal Medicine Department, State Medical University, Zaporozhye, Ukraine.
Centre for Chronic Disease Prevention and Management, College of Health and Biomedicine, Victoria University, St Albans, Australia.
Clin Biochem. 2015 Jun;48(9):562-8. doi: 10.1016/j.clinbiochem.2015.02.003. Epub 2015 Feb 16.
Endothelial-derived microparticles (EMPs) are a novel biological marker of endothelium injury and vasomotion disorders that are involved in pathogenesis of cardiovascular, metabolic, and inflammatory diseases. Circulating levels of EMPs are thought to reflect a balance between cell stimulation, proliferation, apoptosis, and cell death. Increased EMPs may be defined in several cardiovascular diseases, such as stable and unstable coronary artery disease, acute and chronic heart failure, hypertension, arrhythmias, thromboembolism, asymptomatic atherosclerosis as well as renal failure, metabolic disorders (including type two diabetes mellitus, abdominal obesity, metabolic syndrome, insulin resistance) and dyslipidemia. This review highlights the controversial opinions regarding impact of circulating EMPs in major cardiovascular and metabolic diseases and summarizes the perspective implementation of the EMPs in risk stratification models.
内皮细胞衍生的微粒(EMPs)是内皮损伤和血管运动障碍的一种新型生物标志物,参与心血管、代谢和炎症性疾病的发病机制。EMPs的循环水平被认为反映了细胞刺激、增殖、凋亡和细胞死亡之间的平衡。在几种心血管疾病中可发现EMPs水平升高,如稳定型和不稳定型冠状动脉疾病、急慢性心力衰竭、高血压、心律失常、血栓栓塞、无症状动脉粥样硬化以及肾衰竭、代谢紊乱(包括2型糖尿病、腹型肥胖、代谢综合征、胰岛素抵抗)和血脂异常。本综述强调了关于循环EMPs对主要心血管和代谢疾病影响的争议性观点,并总结了EMPs在风险分层模型中的潜在应用。